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Introduction: Healthy bone marrow cell (BMC) infusion improves renal function and limits renal injury in a model
of chronic kidney disease (CKD) in rats. However, BMCs derived from rats with CKD fail to retain beneficial effects,
demonstrating limited therapeutic efficacy. Statins have been reported to improve cellular repair mechanisms.
Methods: We studied whether exposing CKD rat BMCs ex vivo to pravastatin improved their in vivo therapeutic
efficacy in CKD and compared this to systemic in vivo treatment. Six weeks after CKD induction, healthy BMCs,
healthy pravastatin-pretreated BMCs, CKD BMCs or CKD pravastatin-pretreated BMCs were injected into the renal
artery of CKD rats.
Results: At 6 weeks after BMC injection renal injury was reduced in pravastatin-pretreated CKD BMC recipients vs.
CKD BMC recipients. Effective renal plasma flow was lower and filtration fraction was higher in CKD BMC recipients
compared to all groups whereas there was no difference between pravastatin-pretreated CKD BMC and healthy
BMC recipients. Mean arterial pressure was higher in CKD BMC recipients compared to all other groups. In contrast,
6 weeks of systemic in vivo pravastatin treatment had no effect. In vitro results showed improved migration,
decreased apoptosis and lower excretion of pro-inflammatory Chemokine (C-X-C Motif) Ligand 5 in pravastatin-
pretreated CKD BMCs.
Conclusions: Short ex vivo exposure of CKD BMC to pravastatin improves CKD BMC function and their subsequent
therapeutic efficacy in a CKD setting, whereas systemic statin treatment did not provide renal protection.Introduction
The rapidly increasing number of patients with chronic
kidney disease (CKD) worldwide urgently calls for new
interventions. Bone marrow (BM)-derived stem and pro-
genitor cell-based therapies have been proposed as a
promising approach for the treatment of acute kidney
disease and CKD. We recently demonstrated that ad-
ministration of healthy donor bone marrow cells (BMCs)
in an established rat model of CKD reduced progression
of CKD [1]. However, for clinical application of BMC* Correspondence: m.c.verhaar@umcutrecht.nl
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unless otherwise stated.therapy in CKD, the use of autologous BMCs would be
preferred; the challenge is that BMCs derived from CKD
donors are unable to recapitulate therapeutic efficacy
[1]. Therefore, to optimize autologous BMC therapy for
treatment of CKD, we aim to counteract the functional
impairment of CKD BMCs.
Several investigators have reported strategies to im-
prove function of autologous BM-derived progenitor
cell populations. Systemic treatment with lipid-lowering
3-hydroxy-3-methyl-glutaryl Coenzyme A reductase (HMG-
CR) inhibitors (statins) has been shown to augment endothe-
lial progenitor cell (EPC) and mesenchymal stem cell
(MSC) number and function in several disease models,
including cardiovascular diseases [2-4] and hypertensionntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prove cell differentiation, proliferation, migration, angio-
genesis and adhesion and to decrease senescence,
apoptosis and inflammation [7,8], possibly by pleiotropic
effects such as increased nitric oxide (NO) bioavailability,
anti-inflammatory and antioxidant effects [2,3,8,9] and
prevention of cellular senescence via regulation of cell
cycle proteins [10].
However, few studies have investigated the effect of
in vitro or ex vivo statin treatment on cells obtained
from diseased cell source [11-16], and to the best of
our knowledge this is the first study to report the ef-
fects of statin treatment on cells in the context of
CKD. We hypothesized that exposing CKD BMCs to
pravastatin ex vivo would improve their subsequent
in vivo therapeutic efficacy, ameliorating the progres-
sion of renal failure in a rat model of established CKD.
To this end, we studied long-term effects of intra-
arterial delivery of vehicle-pretreated or pravastatin-
pretreated healthy and CKD BMCs on renal hemodynamics
and injury. Our data conclude that while systemic
in vivo treatment with pravastatin does not influence
the course of CKD, a short ex vivo pulse of pravastatinTable 1 Donor characteristics and stratification of donor and
In vitro pravastatin treatment CKD (n = 10)
SNX (%) 66 ± 2
Week 5 SBP (mmHg) 169 ± 28
Week 5 urea (mmol/l) 11 ± 2
Week 5 proteinuria (mg/24 hours) 18 ± 28
Ex vivo pravastatin treatment experiment




SNX (%) – –
Week 5 SBP (mmHg) – –
Week 5 urea (mmol/l) 4.6 ± 0.01 4.1 ± 0.9
Week 5 proteinuria (mg/24 hours) 1.4 ± 0.4 1.8 ± 0.7




SNX (%) 66.3 ± 1.6 66.7 ± 6
Week 5 SBP (mmHg) 156 ± 15 155 ± 16
Week 5 urea (mmol/l) 10.1 ± 0.9 10.3 ± 1
Week 5 proteinuria (mg/24 hours) 21.6 ± 5.6 21.9 ± 6
Systemic in vivo pravastatin treatment
Recipient rats CKD + pravastatin (n = 5) CKD (n
SNX (%) 69 ± 2 66 ± 3
Week 5 SBP (mmHg) 158 ± 19 159 ± 10
Week 5 urea (mmol/l) 12.7 ± 1.1 12.8 ± 1
Week 5 proteinuria (mg/24 hours) 14.6 ± 2.7 16.5 ± 6
At 1 week before BMC or in vivo pravastatin administration (week 5 after SNX), rats we




BMCs were harvested at 6 weeks after CKD induction
from CKD Lewis rats (for characteristics, see Table 1)
and were incubated with or without 1 mmol/l prava-
statin in Dulbecco’s modified Eagle medium (DMEM)
for 2 hours at 37°C. Directly after incubation, cells were
centrifuged and the conditioned medium was stored for
further analysis. Cells were washed, resuspended in 1 ml
DMEM and used for assessment of in vitro migration
and apoptosis. Then 1 × 106 cells were stored in Trizol
(Invitrogen, Grand Island, NY, USA) for RNA extraction.
Bone marrow cell characteristics
Viability and proportions of myeloid and lymphoid cell
precursors were studied by flow cytometry.
Migration assay
Migration of pretreated CKD BMCs was determined
using a modified Boyden chamber assay. Then 300,000recipient rats
+ pravastatin BMC CKD + DMEM BMC
(n = 4)
CKD + pravastatin BMC
(n = 5)
64.0 ± 6.0 69.0 ± 5.5
148 ± 34 152 ± 8
15.0 ± 4.4 15.9 ± 6.9
24 ± 8 49 ± 46
+ pravastatin BMC CKD + DMEM BMC
(n = 10)
CKD + pravastatin BMC
(n = 9)
.4 66.5 ± 3.5 67.6 ± 7.1
159 ± 25 155 ± 19
.5 12.1 ± 3.2 10.6 ± 2.3




re stratified based on plasma urea and SBP. Data presented as mean ± standard
dified Eagle medium; SBP, systolic blood pressure; SNX, subtotal nephrectomy.
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membrane (transwell permeable support system; Corning,
Tewksbury, MA, NY, USA) and the wells below contained
200 ng/ml stromal derived factor 1 alpha (SDF1α), a
strong BMC attractant [17]; vehicle (no SDF1α) was used
as negative control. After 180 minutes, transwells were re-
moved horizontally and 1 ml of 2 mmol/l phosphate-
buffered saline-ethylenediamine tetraacetic acid was added
to the bottom well and incubated for 15 minutes on ice.
Cell suspensions were collected and counted by flow cy-
tometry. The percentage of migrated DMEM-treated
BMCs towards 200 ng/ml SDF1α was set at 100% and
compared with the migration of pravastatin-treated cells.
Apoptosis
Cell suspension (50 μl) was used to create a cell smear,
air dried, fixed with formalin and stored at −20°C. Ter-
minal deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL) staining (Apoptag Plus in situ Peroxidase
kit; Millipore, Temecula, CA, USA) was performed ac-
cording to the manufacturer’s guidelines. The number of
apoptotic cells was determined as the number of
TUNEL-positive cells in the images of 20 randomly se-
lected fields (×200 magnification).
Quantitative real-time PCR
We performed quantitative real-time PCR to determine
the effects of pretreatment of CKD BMCs with prava-
statin on the mRNA expression of endothelial NO syn-
thase, protein kinase B, monocyte chemotactic protein
1, tumor necrosis factor alpha and vascular endothelial
growth factor (ABiPRiSM 790Sequence Detection Sys-
tem; Applied Biosystems, Foster City, CA, USA). The
following TaqMan® Gene Expression Assays (Applied
Biosystems) were used: endothelial NO synthase,
Rn02132634_s1; protein kinase B, Rn00583646_m1;
monocyte chemotactic protein 1, Rn00580555_m1;
tumor necrosis factor alpha, Rn99999017_m1; vascular
endothelial growth factor, Rn00582935_m1; β-actin,
Rn00667869_m1; and calnexin, Rn00596877_m1. Reac-
tions were carried out in duplicate. Cycle time values for
genes of interest were normalized for mean cycle time
values of Calnexin and β-actin, which we previously deter-
mined to be the two most stable housekeeping genes
across all groups using the geNorm program [18], and
expressed relative to a calibrator (the DMEM group), using
the ΔΔCt method. Hence, steady-state mRNA levels were
expressed as the n-fold difference relative to the calibrator.
Cytokine array
A rat cytokine array (R&D Systems, Minneapolis, MN,
USA) of 27 cytokines was performed according to the
manufacturer’s instructions on conditioned medium of
BMC samples obtained from six CKD rats pretreated inDMEM with or without 1 mmol/l pravastatin as re-
ported previously [1,19]. Equal amounts of protein were
loaded on the blots. Each spot on the blot is represented
in duplicate and averages of the two pixel densities were
used to calculate the average pixel density with Image J
software (Rasband W.S. ImageJ, National Institute of
Health, Bethesda, Maryland, USA). Background staining
and spot size were analyzed as recommended by the
manufacturer. In brief, images were converted to 8-bit
inverted tagged image file format files and spots were cir-
cled. Per blot, equal spot sizes were analyzed.
Enzyme-linked immunosorbent assay
An enzyme-linked immunosorbent assay for chemokine
(C-X-C motif ) ligand (CXCL) 5 (Sigma, St. Louis, MO,
USA) was performed according to the manufacturer’s
instructions on conditioned medium of BMC samples
obtained from six CKD rats pretreated in DMEM with
or without 1 mmol/l pravastatin to validate cytokine
array results.
In vivo experiments
Chronic kidney disease induction
The study protocol was approved by the Utrecht Univer-
sity Committee of Animal Experiments. CKD was in-
duced in 8-week-old inbred male Lewis rats (recipients)
and enhanced green fluorescent protein (eGFP)+ Lewis
rats (donors) by two-stage subtotal nephrectomy as de-
scribed previously (t = 0) [1,19]. At week 5, CKD was
confirmed (plasma urea >9 mmol/l).
Experimental design
Effects of ex vivo pravastatin-pretreated BMCs in
established CKD
At week 5 after CKD induction recipient rats (n = 29)
were stratified based on plasma urea and systolic blood
pressure (Table 1). At 6 weeks after subtotal nephrec-
tomy, BMCs were harvested from the femur and tibia of
healthy or CKD eGFP+ donor rats (for donor character-
istics, see Table 1) and suspended in DMEM. The cell
suspension was filtered (100 μm sieve) and counted
(Abbott Cell-Dyn 1800; Abbott Laboratories, Abbott Park,
Illinois, USA). BMCs were incubated with or without 1
mmol/l pravastatin in DMEM for 2 hours at 5% carbon
dioxide in a humidified incubator at 37°C. Cells were
washed to remove pravastatin and resuspended in 500 μl
DMEM. Then 50 × 106 ex vivo pretreated BMC cells were
injected directly into the remnant kidney via the renal ar-
tery as follows: healthy + DMEM BMC recipients (n = 5),
CKD rats injected with healthy eGFP+BMC exposed to
DMEM; healthy + pravastatin BMC recipients (n = 5),
CKD rats injected with healthy eGFP+BMC exposed to
pravastatin; CKD + DMEM BMC recipients (n = 10),
CKD rats injected with CKD eGFP+BMC exposed to
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CKD rats injected with CKD eGFP+BMC exposed to prav-
astatin. Longitudinal measurements were performed at
weeks 7, 9 and 11 after subtotal nephrectomy, and at week
12 (6 weeks after BMC injection) terminal kidney function
was measured (see Terminal kidney function). Directly
thereafter, rats were sacrificed and tissues were collected
and either frozen or fixed in 4% paraformaldehyde for
renal morphology measurements.
Effects of systemic in vivo pravastatin treatment in
established CKD
At week 6 after CKD induction, CKD rats were divided
into two groups: CKD (n = 6), no supplement in drinking
water; and CKD + pravastatin (n = 5), 50 mg/kg/day pra-
vastatin added to drinking water. Longitudinal measure-
ments were performed at weeks 7, 9 and 11, and at week
12 terminal kidney function was measured (see Terminal
kidney function). Directly thereafter, rats were sacrificed
and tissues were collected and either frozen or fixed in 4%
paraformaldehyde for renal morphology measurements.
Longitudinal chronic kidney disease evaluation
Rats were weighed weekly, and at regular intervals 24-hour
urine and blood samples were collected and the systolic
blood pressure was measured by tail cuff sphygmomanom-
etry at weeks 5, 9 and 11. To collect 24-hour urine, rats
were placed in metabolism cages without food for 24
hours, but with free access to water with 2% glucose. For
the systemic in vivo pravastatin treatment studies, prava-
statin was also supplemented to the drinking water during
urine collection. Urine was collected in antibiotic/antimy-
cotic solution (A5955; Sigma) and stored at −80°C. Blood
samples were collected from the tail vein. Urinary protein
levels were measured with Coomassie blue. Sodium and
potassium levels were determined by flame photometry.
NO metabolites were measured (Cayman Chemical, Ann
Arbor, MI, USA). Plasma urea and plasma and urinary
creatinine levels were determined by DiaSys Urea CT
FS (DiaSys Diagnostic Systems, Holzheim, Germany).
Creatinine clearance was calculated by dividing urine
creatinine excretion (μmol/minute/100 g body weight) by
plasma creatinine (μmol/μl). Cholesterol and triglycerides
were determined by DiaSys Cholesterol FS and DiaSys
Triglycerides FS (DiaSys Diagnostic Systems).
Terminal kidney function
Kidney function was assessed by inulin clearance to de-
termine the glomerular filtration rate (GFR) and by
para-amino hippuric acid clearance to determine the ef-
fective renal plasma flow (ERPF) as described previously
[20]. Briefly, rats were anesthetized with isoflurane and
placed on a servo-controlled surgical table to maintain
body temperature at 37°C. A polyethylene-90 catheterwas placed in the left jugular vein for infusion of solutions.
The left femoral artery was cannulated with polyethylene-
50 tubing for measurement of mean arterial pressure and
blood sampling. A polyethylene-90 catheter was placed in
the bladder for urine collection. During surgery, animals
received an intravenous infusion of a 150 mmol/l NaCl so-
lution containing 6% bovine serum albumin. Following
surgery, the infusion was switched to a 150 mmol/l NaCl
solution with 1% bovine serum albumin at the same infu-
sion rate. This infusion was maintained throughout the
experiment. The solution also contained inulin and para-
amino hippuric acid for clearance measurements. A 60-
minute equilibration period was observed before the start
of the 60-minute clearance measurements. During this
clearance, measurement urine was sampled for 15-minute
periods and both before and after the clearance measure-
ment blood was sampled. Clearance and fractional excre-
tions were calculated by standard formulas. Renal blood
flow was calculated from ERPF and hematocrit.
Renal and cardiac morphology
Focal glomerulosclerosis and tubular interstitial damage
were scored on 3 μm periodic acid Schiff-stained paraffin-
embedded slides [1,19]. Glomerular influx of donor BMCs
(eGFP+) and the presence of T cells (CD3+), monocytes/
macrophages (ED-1+), proliferating cells (Ki67+), apoptotic
cells (TUNEL+), cells undergoing DNA damage repair
(γH2AX+) and endothelial cells (JG12+) was counted in 50
glomeruli [21]. The tubular number of T cells (CD3+),
apoptotic cells (TUNEL+) and cells undergoing DNA dam-
age repair (γH2AX+) and influx of donor BMCs (GFP+)
were determined in 20 tubular fields as described previously
[1,19]. Cardiac collagen I and collagen III contents were
stained with Sirius red, visualized with circular polarized
light and digitally analyzed using ImageJ software [22].
The percentage of collagen area was calculated by dividing
the Sirius red stained area by the total image area.
Blood and bone marrow characteristics
Blood and BM were incubated with the cell-permeable
DNA binding dye Vybrant® DyeCycle™ Violet (Invitrogen/
Life, Bleiswijk, the Netherlands) for 30 minutes at 37°C to
allow separation of nucleated cells from debris. Red blood
cells were then lysed by incubation with a 0.8% ammo-
nium chloride lysis solution and samples were washed
with phosphate-buffered saline prior to flow cytometry.
During flow cytometry, debris and dead cells were excluded
by lack of DyeCycle binding and 7-aminoactinomycin D
(Invitrogen) staining, respectively. The remaining cells
were divided into major leukocyte subpopulations (that is,
lymphocytes, monocytes, granulocytes) on the basis of
low-angle forward scatter and orthogonal (‘side’) scatter
properties. Gates for the fluorescent stains and eGFP were
set on fluorescence-minus-one controls, and gates for
Table 2 Bone marrow cell characteristics measured by
fluorescence-activated cell sorting analysis
In vitro pravastatin treated cells
Bone marrow samples DMEM (n = 10) Pravastatin (n = 10)
Granulocytes 31.5 ± 2.6 30.8 ± 2.2
Lymphocytes 37.4 ± 2.6 38.6 ± 2.5
Monocytes 10.3 ± 1.9 10.9 ± 1.9
Stromal cells 7.9 ± 3.6 7.5 ± 3.5
Viability 96.6 ± 3.4 97.0 ± 2.5
Systemic in vivo pravastatin treatment recipients
Bone marrow samples CKD (n = 6) CKD + pravastatin (n = 5)
Granulocytes 23.6 ± 1.5 23.8 ± 1.3
Lymphocytes 31.76 ± 2.8 31.8 ± 2.5
Monocytes 21.3 ± 0.77 16.9 ± 1.3*
Stromal cells 6.04 ± 0.4 7.76 ± 0.50*
Viability 96.8 ± 0.4 97.7 ± 0.01*
Data presented as mean ± standard deviation. CKD, chronic kidney disease;
DMEM, Dulbecco’s modified Eagle medium. *P <0.05 versus CKD.
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center on the contour plot. A volumetric estimate of
leukocyte subpopulation proportions was furthermore ob-
tained using an automated hematology analyzer (Abbott
Cell-Dyn 1800).Quantitative real-time PCR
To ascertain that the dose of pravastatin was sufficient,
the production of HMGCR was evaluated. cDNA was
isolated from frozen liver tissue and expression of
HMGCR (Rn00565598_m1) was determined using quanti-
tative real-time RT-PCR as described for the in vitro
experiments.Figure 1 Effect of in vitro pravastatin treatment on migration capacity of c
medium (DMEM; n = 10); pravastatin (n = 10). BMC, bone marrow cell; CKDStatistical analyses
Data are presented as mean ± standard deviation and
analyzed by analysis of variance (one-way analysis of
variance with a Student–Newman–Keuls post test, two-
way analysis of variance with a Bonferroni post test, and
Student’s t test) with Graphpad Prism software (GraphPad,
La Jolla, CA, USA). P <0.05 was considered significant.Results
In vitro experiments
In vitro pravastatin pre-treatment of BMCs improves BMC
function
Pravastastin treatment of CKD BMC did not induce differ-
ences in myeloid and lymphoid precursor cell composition
(Table 2). CKD + pravastatin BMCs showed increased
migration towards 200 ng/ml SDF1α as compared with
CKD + DMEM BMCs in eight out of 10 rats (P = 0.014;
Figure 1). Fewer apoptotic cells were found in CKD +
pravastatin BMCs versus CKD + DMEM BMCs in eight
out of 10 rats (P = 0.16; Figure 2). Pravastatin treatment
of CKD BMCs did not alter mRNA expression of tumor
necrosis factor alpha, endothelial NO synthase, protein
kinase B, monocyte chemotactic protein 1 or vascular
endothelial growth factor genes (Table 3). Of the 27 cy-
tokines tested on a cytokine array, we could only detect
expression of four cytokines. Pravastatin treatment of
CKD BMCs decreased the secretion of proinflammatory
CXCL5 and increased CXCL7, whereas secretion of L-
selectin and soluble intracellular adhesion molecule was
not different between DMEM-treated and pravastatin-
treated CKD BMCs (Figure 3). Decreased CXCL5 secre-
tion by CKD + pravastatin BMCs compared with
DMEM-treated CKD BMCs was confirmed by enzyme-
linked immunosorbent assay (60 ± 12 vs. 98 ± 31 pg/ml;
P = 0.0045).hronic kidney disease bone marrow cells. Dulbecco’s modified Eagle
, chronic kidney disease; SDF, stromal derived factor.
Figure 2 Effect of in vitro pravastatin treatment on apoptosis in chronic kidney disease bone marrow cells. Dulbecco’s modified Eagle medium
(DMEM; n = 10); pravastatin (n = 10). TUNEL, Terminal deoxynucleotidyl transferase dUTP nick end labeling.
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Ex vivo pravastatin pre-treatment of CKD BMC improves
in vivo therapeutic efficacy
As compared with healthy + DMEM BMC recipients,
CKD + DMEM BMC recipients had a 38% lower GFR
and 45% lower ERPF at week 12. However, in CKD +
pravastatin BMC recipients the GFR and ERPF were not
significantly different compared with healthy + DMEM
BMC recipients (Table 4). Terminal mean arterial pressure
was 20 mmHg lower in CKD + pravastatin BMC recipi-
ents compared with CKD + DMEM BMC recipients and
not different from either healthy + DMEM BMC recipi-
ents or healthy + pravastatin BMC recipients (Table 4).
Hematocrit was lower in CKD + DMEM BMC recipients
versus healthy + DMEM BMC recipients, but higher in
CKD + pravastatin BMC recipients versus CKD BMC re-
cipients (Table 4). The filtration fraction was higher in
CKD BMC recipients versus healthy BMC recipients,
whereas in CKD + pravastatin BMC recipients the filtra-
tion fraction was not significantly different versus healthy
+ DMEM BMC recipients (Table 4). Terminal body, kid-
ney and heart weights did not differ (Table 4).Table 3 Gene expression in chronic kidney disease bone
marrow cells not changed after in vitro treatment with
pravastatin
DMEM (n = 10) Pravastatin (n = 10) P value
TNFα 1.000 ± 1.290 0.868 ± 0.969 0.7504
eNOS 1.000 ± 4.609 2.161 ± 2.874 0.5422
PKB 1.000 ± 0.889 0.905 ± 0.5512 0.6906
MCP-1 1.000 ± 1.254 1.191 ± 0.6933 0.6101
VEGF 1.000 ± 0.566 0.687 ± 0.464 0.0807
Data presented as mean ± standard deviation, expressed as fold change.
DMEM, Dulbecco’s modified Eagle medium; eNOS, endothelial nitric oxide
synthase; MCP-1, monocyte chemotactic protein 1; PKB, protein kinase B; TNFα,
tumor necrosis factor alpha; VEGF, vascular endothelial growth factor.At week 11, plasma urea was higher in CKD + DMEM
BMC recipients compared with healthy + DMEM BMC
recipients (16.1 ± 7.9 vs. 10.7 ± 1.7 mmol/l, P < 0.05),
whereas CKD + pravastatin BMC recipients (12.9 ± 3.2
mmol/l) were not significantly different from healthy +
DMEM BMC recipients (10.7 ± 1.7 mmol/l) (Figure 4A).
Diuresis, proteinuria, creatinine clearance, and excretion
of NO metabolites were not significantly different between
groups, but from weeks 7 to 11 natriuresis was higher in
CKD + pravastatin BMC recipients versus CKD + DMEM
BMC recipients (1,680 ± 473 vs. 1,176 ± 233; P <0.05;
Figure 4B,C,D,E,F).
In all CKD groups, only 10% of glomeruli were completely
normal, confirming severe kidney injury. The number of
totally sclerotic glomeruli was higher in CKD + DMEMFigure 3 Cytokine expression in chronic kidney disease bone
marrow cells after exposure to vehicle (DMEM) or pravastatin in vitro.
Dulbecco’s modified Eagle medium (DMEM; n = 6); pravastatin (n = 6).
CXCL, chemokine (C-X-C motif) ligand; sICAM, soluble intracellular
adhesion molecule.
Table 4 Terminal measurements of bone marrow cell recipients with post hoc P values













BMC vs. healthy +
DMEM BMC
CKD + DMEM
BMC vs. CKD +
pravastatin BMC
Body weight (g) 376 ± 23 379 ± 26 359 ± 38 373 ± 22 ns ns
Heart weight
(g/100 g BW)
0.44 ± 0.07 0.44 ± 0.03 0.47 ± 0.08 0.44 ± 0.05 ns ns
Kidney weight
(g/100 g BW)
0.59 ± 0.07 0.56 ± 0.05 0.53 ± 0.06 0.55 ± 0.04 0.063 ns
MAP (mmHg) 149 ± 28 146 ± 35 173 ± 21 153 ± 21 0.095 0.091
GFR (μl/minute/100 g) 371 ± 68 352 ± 119 237 ± 159 261 ± 149 0.057 ns
ERPF (μl/minute/100 g) 1538 ± 224 1388 ± 502 844 ± 626* 1157 ± 359 <0.05 ns
Hematocrit 0.45 ± 0.01 0.44 ± 0.01 0.42 ± 0.03* 0.46 ± 0.02† <0.05 <0.05
FF (%) 24.1 ± 2.4 26.2 ± 4.7 29.9 ± 4.5* 26.4 ± 3.7 <0.05 0.071
Data presented as mean ± standard deviation. BMC, bone marrow cell; BW, body weight; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium;
ERPF, effective renal plasma flow; FF, filtration fraction; GFR, glomerular filtration rate; MAP, mean arterial pressure. *P <0.05 compared with healthy BMC
recipients, †P <0.05 compared with CKD BMC recipients. Trends (P <0.1) are only indicated with the exact P value.
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ents (P <0.05). Comparing the number of partly and to-
tally sclerotic glomeruli between CKD + DMEM BMC
recipients and CKD + pravastatin BMC recipients re-
vealed a favorable shift to better preserved glomeruli in
CKD + pravastatin BMC recipients (P <0.05; Figure 5A).
Tubular interstitial inflammation, tubular atrophy and
interstitial fibrosis were all lower in CKD + pravastatin
BMC recipients versus CKD + DMEM BMC recipients
(Figure 5B). The number of glomerular inflammatory
cells (ED1+ and CD3+) tended to be higher in CKD +
DMEM BMC recipients compared with all other
groups. Tubular CD3+ influx was most abundant in
CKD + DMEM BMC recipients (Table 5). Cardiac fi-
brosis tended to be more abundant in CKD + DMEM
BMC recipients compared with healthy BMC + DMEM
recipients, as reported previously [23]. In CKD + prav-
astatin BMC recipients, cardiac fibrosis tended to be
reduced compared with CKD + DMEM BMC recipi-
ents (15.3 ± 7.6 vs. 20.5 ± 4.7%; P = 0.085). Healthy +
pravastatin BMCs did not influence cardiac fibrosis
(healthy + DMEM BMC recipients: 16.7 ± 6.5 vs. healthy
+ pravastatin BMC recipients: 16.8 ± 6.7%).
The number of proliferating glomerular cells (Ki67+),
endothelial cells (JG12+), and apoptotic cells (TUNEL+)
were not significantly different between groups (Table 5).
No difference was found in the number of tubular apop-
totic (TUNEL+) cells, cells expressing DNA damage re-
pair marker γH2AX+ (Table 5), or the number of eGFP+
cells. As shown previously, eGFP+ cells were detected in
the remnant kidney and heart but only in low numbers.
No integration of these cells was observed and most
were attached to the endothelial lining of small vessels
[1]. No differences were observed in blood counts
(Table 6).Systemic in vivo treatment of CKD rats with pravastatin
does not reduce CKD progression
CKD rats developed hypertension, mild uremia, anemia
and proteinuria (Figure 6). Systemic 6-week in vivo prav-
astatin treatment did not influence the body weight,
GFR, ERPF, filtration fraction or hematocrit (Table 7).
Furthermore, no differences in blood counts (Table 6),
focal glomerulosclerosis and tubulo-interstitial damage
(Table 8), cardiac fibrosis (3.54 ± 2.20 vs. 4.79 ± 2.71%)
or NO metabolite excretion (Figure 6) were observed be-
tween CKD and CKD + pravastatin rats. Cholesterol did
not differ between CKD + pravastatin-treated rats and
CKD rats; however, triglycerides were significantly lower
in CKD + pravastatin-treated rats (Table 7). Systemic
pravastatin decreased the number of monocytes and
increased the stromal cell population in the BM
(Table 2) and increased hepatic HMGCR mRNA ex-
pression (Table 7).
Discussion
The present study demonstrates for the first time that
BMC dysfunction in CKD can be reversed by short-term
(2 hours) pretreatment with pravastatin outside the CKD
environment and that this effect persists when the cells
are returned to the CKD environment, providing aug-
mented therapeutic efficacy in vivo.
Our recent studies have shown that a single injection
of healthy BMCs in rats with established CKD slowed
progression of the disease, probably via paracrine ac-
tions. Less disease progression was characterized by in-
creased glomerular capillary density and less sclerosis.
Injection of BMCs derived from CKD rats was less ef-
fective [1], suggesting that CKD induces alterations in
(paracrine) functions of BMC which reduce endothelial
regenerative capacity and efficacy of CKD BMC therapy
Figure 4 Effects of ex vivo exposure of healthy and chronic kidney disease bone marrow cells to pravastatin or DMEM on longitudinal plasma
and urinary variables of chronic kidney disease recipients. (A) Urea. (B) Diuresis. (C) Proteinuria. (D) Creatinine clearance. (E) Nitric oxide (NO)
metabolites. (F) Natriuresis. Week 5 represents 1 week before BMC injection. Data presented as mean ± standard deviation. BMC, bone marrow
cell; BW, body weight; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; SNX, subtotal nephrectomy.
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beneficial effects on endothelial as well as on BM-
derived EPC and MSC function both after in vitro incu-
bation and after systemic in vivo treatment [5,7-9]. Here
we show that short-term ex vivo pretreatment with prav-
astatin reverses paracrine dysfunction in BMCs obtained
from rats with established CKD, resulting in preserved
renal morphology in recipient rats with CKD.
The role of transdifferentiation and incorporation of
BMCs in enhancing tissue regeneration has been ques-
tioned. BMCs appear to have a supportive function, se-
creting growth factors and cytokines, thereby stimulating
resident cells to engage in regeneration [24]. Using a cyto-
kine array we showed that short-term pravastatin pretreat-
ment influences paracrine factor secretion by BMCs. CKD
+ pravastatin BMCs significantly decreased expression ofthe proinflammatory chemokine CXCL5, which was
shown to be involved in the recruitment and activation of
polymorphonuclear neutrophils and in stimulation of local
production of cytokines that have proapoptotic effects
[25]. Our findings are in accordance with previous reports
that atorvastatin dose-dependently inhibits basal CXCL5
production in human umbilical vein endothelial cells [26]
and that simvastatin inhibited CXCL5 release from per-
ipheral blood mononuclear cells [27]. In our experiments,
renal influx of inflammatory cells was lowered in CKD +
pravastatin BMC recipients versus CKD + DMEM BMC
recipients. In glomeruli, there was a trend towards more
ED-1+ macrophages and CD3+ T cells in CKD + DMEM
BMC recipients and the influx in CKD + pravastatin BMC
recipients was lower and comparable with both healthy +
DMEM BMC recipients and healthy + pravastatin BMC
Figure 5 Effects of ex vivo exposure of healthy and chronic kidney disease bone marrow cells to pravastatin on renal morphology in chronic
kidney disease recipients. (A) Focal glomerulosclerosis. (B) Tubulo-interstitial damage. CKD rats received healthy + DMEM BMCs (n = 5),
healthy + pravastatin BMCs (n = 5), CKD + DMEM BMCs (n = 10) or CKD + pravastatin BMCs (n = 9). *P <0.1 versus healthy BMC recipients,
$P <0.1 and $$P <0.05 versus CKD + DMEM BMC recipients. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified
Eagle medium; FGS, focal glomerulosclerosis.
Table 5 Glomerular and tubular histological


















CD3 0.68 ± 0.34 0.72 ± 0.33 0.76 ± 0.19 0.67 ± 0.27
ED-1 7.4 ± 1.0 5.0 ± 2.9 10.5 ± 5.5 7.9 ± 1.9
Ki67 8.0 ± 0.76 6.4 ± 1.7 7.8 ± 1.8 7.8 ± 2.3
TUNEL 2.6 ± 1.3 2.1 ± 1.3 7.0 ± 4.6 4.4 ± 3.7
γH2AX 1.5 ± 1.6 0.6 ± 0.4 1.2 ± 0.8 1.4 ± 0.8
GFP+ 7.0 ± 6.6 2.5 ± 0.7 2.3 ± 1.9 5.2 ± 2.9
JG12 42.5 ± 10 44.4 ± 9.9 42.8 ± 12.5 48.1 ± 9.0
Tubular
CD3 81 ± 11 96 ± 45 122 ± 59 98 ± 27
TUNEL 35 ± 24 65 ± 59 147 ± 116 95 ± 79
γH2AX 5.0 ± 1.6 4.3 ± 2.0 6.1 ± 2.8 5.3 ± 1.5
GFP+ 83 ± 82 31 ± 24 23 ± 20 50 ± 38
Data presented as mean ± standard deviation per 50 glomeruli or 20 tubular
fields. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s
modified Eagle medium; GFP, green fluorescent protein; TUNEL, terminal
deoxynucleotidyl transferase dUTP nick end labeling.
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of in vitro pravastatin-pretreated BMCs. Increased para-
crine function can explain why we did not observe an
increase in the number of eGFP+ cells in the remnant
kidney. Our observations that few eGFP+ BMCs were
found in kidney sections of all recipients, and that those
found were in close proximity to the microvasculature
but did not differentiate into endothelial cells, are con-
sistent with paracrine actions of BMCs reported by
others [28,29].
Impaired BMC function in CKD rats is consistent with
clinical studies reporting impaired function of BM-
derived EPCs obtained from CKD patients [30,31]. We
showed previously that culturing healthy BM mono-
nuclear cells in uremic serum caused reduced outgrowth
of EPCs, suggesting that uremic serum contains either
impairing toxins or lacks essential stimulants to support
EPC function [31]. Indeed, better in vivo removal of
uremic toxins in CKD patients has been shown to im-
prove EPC function [32,33]. However, culturing of CKD
BMCs in nonuremic conditions in vitro could not reverse
the impairment in outgrowth towards EPCs or EPC func-
tion [31,34]. In our study, 2 hours of incubation in DMEM
outside a CKD environment did not reverse BMC dys-
function. Importantly, our experiments show that 2 hours
of incubation with pravastatin improved rat CKD BMC
Table 6 Blood cell counts
Ex vivo pravastatin pretreatment experiment recipients
Blood
samples
Healthy + DMEM BMC
recipients (n = 5)
Healthy + pravastatin BMC
recipients (n = 5)
CKD + DMEM BMC
recipients (n = 10)
CKD + pravastatin BMC
recipients (n = 9)
White blood
cells
5.86 ± 1.20 5.52 ± 0.93 4.63 ± 1.05 5.42 ± 1.18
Lymphocytes 3.30 ± 1.35 2.54 ± 0.29 2.60 ± 0.86 2.94 ± 0.51
Midpopulation 1.58 ± 0.29 1.56 ± 0.31 1.18 ± 0.28 1.59 ± 0.45
Granulocytes 0.98 ± 0.45 1.38 ± 0.53 0.84 ± 0.35 1.08 ± 0.52
Red blood
cells
6.66 ± 0.40 6.59 ± 0.36 6.24 ± 0.59 6.63 ± 0.23
Hemoglobin 8.06 ± 0.47 7.90 ± 0.42 7.63 ± 0.72 7.86 ± 0.29
Hematocrit 0.33 ± 0.05 0.33 ± 0.019 0.31 ± 0.029 0.33 ± 0.010
Mcv 49.08 ± 0.83 50.08 ± 1.08 50.10 ± 2.09 49.35 ± 0.78
Mchc 24.38 ± 0.22 23.94 ± 0.38 24.18 ± 0.43 24.08 ± 0.36
Rdw 15.44 ± 0.43 15.22 ± 0.29 15.63 ± 1.125 15.151 ± 0.818
Platelets 736 ± 68 697 ± 49 634 ± 99 699 ± 55
Systemic in vivo pravastatin treatment
Blood
samples
CKD (n = 6) CKD + pravastatin (n = 5)
White blood
cells
4.81 ± 0.89 4.50 ± 1.16
Lymphocytes 2.87 ± 0.59 2.90 ± 0.97
Midpopulation 1.27 ± 0.39 0.90 ± 0.19
Granulocytes 0.65 ± 0.16 0.68 ± 0.13
Red blood
cells
6.38 ± 0.22 6.25 ± 0.15
Hemoglobin 7.58 ± 0.32 7.52 ± 0.18
Hematocrit 0.32 ± 0.01 0.31 ± 0.01
Mcv 49.37 ± 0.79 49.96 ± 0.32
Mchc 24.05 ± 0.25 24.14 ± 0.23
Rdw 15.13 ± 0.63 15.14 ± 0.68
Platelets 681 ± 42 666 ± 41
Data presented as mean ± standard deviation. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium. Mcv, Mean
Corpuscular Volume; Mchc, Mean Corpuscular Hemoglobin Concentration; Rdw, Relative Distribution Width.
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if confirmed in human CKD. Induction of improvement
in CKD BMC function by HMGCR inhibition within 2
hours is remarkable but seems consistent with previous
reports showing that short-term statin incubation (<10
minutes) induces a rapid elevation of NO production in
endothelial cells [35] and rapid (<30 minutes) induction of
Akt-mediated phosphorylation of endothelial NO synthase
leading to NO production [36].
Filtration fraction was increased in CKD + DMEM
BMC recipients versus healthy BMC recipients (P <0.05),
indicating a less well preserved glomerular structure.
Mean arterial pressure was 20 mmHg lower in rats that
received CKD + pravastatin CKD BMCs or healthy +
DMEM BMCs compared with recipients that received
CKD + DMEM BMCs, and healthy + DMEM BMC,healthy + pravastatin BMC and CKD + pravastatin BMC
recipients tended to have a higher natriuresis per 24 hours
versus CKD + DMEM BMC recipients. Blood pressure
lowering of 20 mmHg has major renal and cardiovascular
implications such as decreased risk of stroke [37], myocar-
dial infarction, cardiac failure [38] and peripheral arterial
disease and an increased life expectancy [39]. Consistently,
we observed significantly less glomerulosclerosis, tubular
inflammation, atrophy and fibrosis in remnant kidneys of
rats that received CKD + pravastatin BMCs compared
with CKD + DMEM BMC recipients. Cardiac fibrosis
tended to be increased in CKD + DMEM BMC recipients
compared with CKD + pravastatin BMC recipients. Ex
vivo pravastatin treatment did not further improve renal
function or structure or decrease cardiac fibrosis in
healthy + pravastatin BMC recipients compared with
Figure 6 Effects of systemic in vivo exposure to pravastatin on longitudinal variables in chronic kidney disease recipients. (A) Systolic blood
pressure. (B) Urea. (C) Hematocrit. (D) Proteinuria. SNX, subtotal nephrectomy.
Table 7 Terminal measurements after systemic in vivo
pravastatin treatment
Week 12 CKD (n = 6) CKD + pravastatin
(n = 5)
Body weight (g) 357 ± 24 369 ± 16
Heart weight (g/100 g BW) 0.45 ± 0.02 0.42 ± 0.03*
Kidney weight (g/100 g BW) 0.57 ± 0.02 0.57 ± 0.04
MAP (mmHg) 168 ± 19 164 ± 19
GFR (μl/minute/100 g) 340 ± 60 332 ± 41
ERPF(μl/minute/100 g) 1335 ± 291 1221 ± 189
Hematocrit 0.41 ± 0.02 0.40 ± 0.02
FF (%) 28 ± 3 26 ± 2
Cholesterol (mmol/l) 2.89 ± 0.53 2.73 ± 0.46
Triglycerides (mmol/l) 1.42 ± 0.38 0.70 ± 0.37*
Fold change hepatic
HMGCR mRNA expression
1.000 ± 0.56 1.584 ± 0.65
Data presented as mean ± standard deviation. BW, body weight; CKD, chronic
kidney disease; ERPF, effective renal plasma flow; FF, filtration fraction; GFR,
glomerular filtration rate; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase;
MAP, mean arterial pressure. *P <0.05 compared with CKD.
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pravastatin BMC recipients cardiac fibrosis was signifi-
cantly decreased compared with CKD + DMEM BMC
recipients, indicating that pravastatin specifically cor-
rected CKD BMC function. We have not compared dif-
ferent statins in our experimental setup, and therefore
our study does not allow conclusions as to whether this
phenomenon is a specific effect of pravastatin or a gen-
eric statin effect.Table 8 Longitudinal, terminal and histological
measurements after in vivo pravastatin treatment
CKD (n = 6) CKD + pravastatin (n = 5)
Focal glomerulosclerosis (%)
Normal 32.9 ± 7.6 23.4 ± 13.1
Partial 48.1 ± 10.6 62.7 ± 10.4
Total 19.0 ± 6.7 14.0 ± 15.8
Tubulo-interstitial damage
Fibrosis 0.78 ± 0.31 0.85 ± 0.14
Inflammation 1.72 ± 0.54 1.66 ± 0.22
Atrophy 1.09 ± 0.65 0.56 ± 0.09
Data presented as mean ± standard deviation. CKD, chronic kidney disease.
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with pravastatin did not influence CKD progression or
renal fibrosis in our model of established CKD. Although
cholesterol-lowering effects of statins do not occur in ro-
dents, pleiotropic effects have been reported [40] such
as reduced inflammation and oxidative stress, enhanced
endothelial function and increased mobilization and
function of EPCs. Some older studies showed beneficial
effects of statins on renal function and morphology in
experimental CKD, although others reported harmful ef-
fects such as induction of renal fibrosis [41,42]. Recently,
Geng and colleagues performed a meta-analysis on the
effect of statins on renal function (estimated GFR and
proteinuria) in patients with CKD. The analysis showed
that the beneficial effect of statins on renal function may
be dose and time dependent and that statins are well
tolerated in patients with National Kidney Foundation
Kidney Disease Outcomes Quality Initiative stages 1 to
3. However, the effect of statins on renal function in
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative stages 4 and 5 remains controversial
[43]. The lack of effect of statin treatment in our in vivo
study cannot be explained by insufficient dosing of prav-
astatin. Similar statin doses have previously been shown
to increase EPC mobilization in mice [44]. Furthermore,
we observed a significant decrease in triglycerides and
an increase in HMGCR mRNA expression after sys-
temic pravastatin treatment, which indicates that the
dose was sufficient to affect the mevalonate pathway,
and is in agreement with Zager and colleagues [45].Conclusions
Short-term pretreatment of CKD BMCs with pravastatin
reversed CKD BMC dysfunction and improved the cells’
therapeutic efficacy in vivo. Our data suggest that this is
due to an improvement in their paracrine profile. In
contrast, systemic in vivo pravastatin treatment did not
attenuate the progressive course of CKD. Our findings
have relevance for potential clinical application of BMC
therapy in patients with CKD as clinical application
would involve autologous – and thus CKD – BMCs to
avoid immunological reactions. If confirmed for human
CKD BMCs, our findings will provide a basis for devel-
opment of clinical trials and application of autologous
BMC-based therapies in human CKD.Abbreviations
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